Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. 9-699-016
Published by: Harvard Business Publishing
Originally published in: 1999
Version: 23 June 2000
Length: 24 pages
Data source: Field research

Abstract

Describes the creation and operation of the initial two heavyweight teams for new drug development and launch. The primary focus is on one of those two teams, Evista, although comparisons to the other team, Zyprexa, are included. Lilly must decide the next phase (post launch) for managing Evista''s rollout.; Operational realities of heavyweight development teams and their transition following product launch.

About

Abstract

Describes the creation and operation of the initial two heavyweight teams for new drug development and launch. The primary focus is on one of those two teams, Evista, although comparisons to the other team, Zyprexa, are included. Lilly must decide the next phase (post launch) for managing Evista''s rollout.; Operational realities of heavyweight development teams and their transition following product launch.

Related